ea0056gp4 | Acromegaly | ECE2018
Coopmans Eva C
, Muhammad Ammar
, Janssen Joseph AMJL
, van der Lely Aart J
, Neggers Sebastian JCMM
Background: In the core phase of the PAPE study until 24 weeks we have shown that switching to pasireotide LAR (PAS-LAR) in well-controlled acromegaly patients receiving combination therapy of somatostatin analogues and pegvisomant (PEGV), normalizes IGF1 levels in the majority of patients. PAS-LAR induced a significant PEGV sparing effect, but this was at the expense of a higher incidence of diabetes. This extension study until 48-weeks assesses the efficacy, safety and quali...